Corcept Therapeutics Incorporated (CORT) — Quality & forensics
As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 23
- Quality 48
- Growth 59
- Balance sheet 91
- Cash quality 53
- Capital allocation 37
- Momentum 90
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the CORT chart & overview · the earnings record
FAQ · from the current data · as of 2026-09-18
Quick answers
What is Corcept Therapeutics Incorporated's Closelook quality reading?
The composite reads 57/100 across 7 modules, as of 2026-09-18: valuation 23, quality 48, growth 59, balance sheet 91, cash quality 53, capital allocation 37, momentum 90. Closelook scores are research diary readings, not ratings or investment advice.
What is Corcept Therapeutics Incorporated's Altman Z-Score?
41.02, which sits in the safe zone (above 2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Corcept Therapeutics Incorporated's Piotroski F-Score?
4 of 8, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Corcept Therapeutics Incorporated's Beneish M-Score indicate?
-2.75 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Mentioned on Closelook
Where CORT appears in the diary — 1 piece, newest first. Every link is our own writing.
Go deeper
Dailies
- A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000
Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG…
Related in the Closelook universe
then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- ONC BeiGene, Ltd.industry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- MRNA Moderna Incindustry
- TWST Twist Bioscience Corpindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- SMMT Summit Therapeutics PLCindustry
- RXRX Recursion Pharmaceuticals Incindustry
- HALO Halozyme Therapeutics Incindustry
- GMAB Genmab ASindustry
- IBRX Immunitybio Incindustry
- SRPT Sarepta Therapeutics Incindustry
- CRSP Crispr Therapeutics AGindustry
- TGTX TG Therapeutics Incindustry
- EXEL Exelixis Incindustry
- INCY Incyte Corporationindustry
- MRVI Maravai Lifesciences Holdings Incindustry